Physician profile
Stuart Silberstein
NPI 1982787321
$824.38
in general payments reported to CMS, 2019-2025
13 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.22 · 2020: $12.86 · 2021: $66.83 · 2022: $180 · 2023: $116 · 2024: $188 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $553.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $552.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $279.40 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Penumbra, INC. | $174.53 | 2025 | Indigo System |
| Mallinckrodt Hospital Products INC. | $115.53 | 2022-2023 | Acthar |
| Harmony Biosciences LLC | $43.33 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $39.36 | 2020-2023 | Breztri |
| Teva Pharmaceuticals USA, INC. | $36.73 | 2022-2024 | Ajovy |
| Mylan Specialty L.P. | $27.59 | 2023-2024 | Yupelri |
| Masimo Corporation | $25.11 | 2023 | Set and Rainbow Set |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.01 | 2021-2023 | Spiriva Respimat |
| Insmed, INC. | $16.56 | 2025 | Arikayce |
| Regeneron Healthcare Solutions, INC. | $14.39 | 2024 | Dupixent |
| Amgen INC. | $14.01 | 2025 | Tezspire |
| Axsome Therapeutics, INC. | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Silberstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.